# Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

> **NCT07493330** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 86 (estimated)

## Conditions studied

- PTCL
- Refractory

## Interventions

- **DRUG:** Zeprumetostat+Azacitadine
- **DRUG:** Zeprumetostat+Decitabine
- **DRUG:** Zeprumetostat+Chidamide
- **DRUG:** Zeprumetostat+Golidocitinib

## Key facts

- **NCT ID:** NCT07493330
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2029-12-12
- **Final completion:** 2030-12-12
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493330, "Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07493330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*